北京瑞迈特医疗科技股份有限公司 信息披露暂缓与豁免制度 第一章 总则 （一）业务部门、子公司或者其他信息披露义务人应当及时将暂缓、豁免披露 事项及其对应的业务合同、主管机关的保密要求、涉及公司商业秘密的说明等资料 报送公司董事会秘书； （二）董事会秘书收到暂缓、豁免事项的文件后，应及时对暂缓、豁免事项的 文件进行预审核，董事会秘书对相关文件有疑问的，有权向业务部门、子公司或者 其他信息披露义务人进一步了解情况，相关业务部门、子公司或者信息披露义务人 应当配合提供信息或资料； 1 （三）董事会秘书收集完备暂缓、豁免披露事项的全部信息或资料后，由董事 会秘书准备暂缓、豁免披露申请表，董事会秘书签字同意后提交给公司董事长，董 事长在申请表上签字同意后方可启动申请暂缓、豁免披露信息。 董事会秘书和董事长签字的申请表及其相关书面资料，将作为公司暂缓、豁免 披露事项的档案，由公司董事会秘书登记入档。 第一条 为规范北京瑞迈特医疗科技股份有限公司（以下简称"公司"）信息披 露暂缓与豁免披露行为，根据《中华人民共和国证券法》《上市公司信息披露管理 办法》《上市公司信息披露暂缓与豁免管理规定》等相关法律、法规、规范性文件 及《 ...

北京瑞迈特医疗科技股份有限公司 舆情管理制度 （二） 一般舆情：指除重大舆情之外的其他舆情。 第一章 总则 第一条 为了提高北京瑞迈特医疗科技股份有限公司（以下简称"公司"） 应对舆情的能力，建立快速反应和应急处置机制，充分发挥网络互动优势，正确 把握和引导网络舆论导向，及时、妥善处理各类舆情对公司股价、商业信誉及正 常生产经营活动造成的影响，切实保护投资者合法权益，根据《深圳证券交易所 创业板股票上市规则》等相关法律法规、规范性文件和《北京瑞迈特医疗科技股 份有限公司章程》（以下简称"《公司章程》"），特制定本制度。 第二条 本制度所称舆情包括： （一） 报刊、电视、网络等媒体对公司进行的不实报道、负面报道； （二） 社会上存在的已经或将给公司造成不良影响的传言或信息； （三） 可能或者已经影响社会公众投资者投资取向，造成公司股价异常波 动的信息； （四） 其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第三条 舆情信息的分类： （一） 重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价 格变动 ...

北京瑞迈特医疗科技股份有限公司 第七条 公司设总经理一名，副总经理若干名。 第八条 公司经理人员的任职资格、产生方式、任期、薪酬待遇，按《公 司章程》及公司其他管理制度和董事会有关决议的规定执行。 总经理工作细则 第一章 总则 第一条 为规范北京瑞迈特医疗科技股份有限公司（以下简称"公司"） 总经理、副总经理和其他高级管理人员（以下简称"经理人员"）的职务行为， 提高公司管理效率和管理水平，根据《公司法》等法律、法规、规范性文件及 《北京瑞迈特医疗科技股份有限公司章程》（以下简称"《公司章程》"）的 相关规定，制订本细则。 第二条 本细则所称公司经理人员，包括公司总经理、副总经理，以及 《公司章程》规定的其他高级管理人员。 第三条 本细则对公司经理人员的主要管理职能作出规定，并对公司总 经理、副总经理的职责权限与分工作出规定。 第四条 公司经理人员应当勤勉尽责地履行职责，具备正常履行职责所 需的必要的知识、技能和经验，并保证有足够的时间和精力履行职责。 第五条 公司经理人员向董事会负责并接受董事会的监督和指导。 第六条 公司经理人员应当严格执行董事会决议、股东会决议等相关决 议，不得擅自变更、拒绝或消极执行相 ...

北京瑞迈特医疗科技股份有限公司 信息披露与投资者关系管理制度 第一章 总则 第一条 为规范北京瑞迈特医疗科技股份有限公司（以下简称"公司"） 信息披露行为，保证公司披露信息真实、准确、完整、及时，根据《中华人民 共和国证券法》《上市公司信息披露管理办法》（以下简称"《信息披露管理办 法》"）等相关法律、法规、规范性文件及《北京瑞迈特医疗科技股份有限公司 章程》（以下简称"《公司章程》"）等的有关规定，制定本制度。 第二条 本制度所称"重大信息"是指对公司股票及其衍生品种（以下 统称"证券"）的交易价格可能或已经产生较大影响的信息，具体标准根据《信 息披露管理办法》《深圳证券交易所创业板股票上市规则》（以下简称"《上市 规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》（以下简称"《规范运作指引》"）等法律法规、规范性文件、自律规 则的有关规定确定。 第三条 本制度所称公开披露是指公司及相关信息披露义务人按《信息 披露管理办法》等法律、行政法规、部门规章、规范性文件、《上市规则》及 深圳证券交易所的相关规定，在深圳证券交易所的网站和中国证监会规定条件 的媒体上公告信息。未公 ...

北京瑞迈特医疗科技股份有限公司 2025 年半年度报告全文 证券代码：301367 证券简称：瑞迈特 公告编号：2025-050 北京瑞迈特医疗科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 北京瑞迈特医疗科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人庄志、主管会计工作负责人暴楠及会计机构负责人(会计主管 人员)曹丽娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异。 公司在本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分，详细阐述了未来公司经营中可能发生的风险及应对措施， 敬请投资者予以关注。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Ruimait Medical Technology Co., Ltd., particularly in the respiratory health medical device sector [1][2] - As of August 22, the company's stock closed at 96.48 yuan, down 2.89%, with a rolling PE ratio of 48.73 times and a total market capitalization of 8.645 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Ruimait at the 86th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year, with a gross profit margin of 49.57% [2] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents [1] - The main products of the company include various types of sleep respiratory machines and monitoring devices, indicating a strong focus on innovation and product development in the respiratory health field [1]

Group 1 - The core point of the article highlights the financing activities of Ruimaite, indicating a net buying amount of 2.6008 million yuan on August 20, with a total financing buy amount of 0.11 billion yuan, ranking 2893rd in the market [1] - Over the last three trading days from August 15 to August 20, Ruimaite experienced financing buy amounts of 0.07 billion yuan, 0.19 billion yuan, and 0.11 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold short, but there was a net buying of 0.0004 million shares [2]

Summary of the Conference Call for 瑞迈特 Company Overview - 瑞迈特 has significantly increased its market share in the US due to the recall of Philips products in 2022, but is expected to experience a decline in revenue and profit in 2023-2024 due to inventory destocking overseas. Growth is anticipated to resume starting Q4 2024, with improvements in gross and net margins indicating future growth potential [2][3][5]. Revenue Structure and Market Characteristics - The company's revenue primarily comes from home respiratory devices and consumables, with home respiratory devices accounting for a major portion. The US market represents nearly 30% of total revenue, while overseas markets account for about 50%. The introduction of a new noise-free respiratory device is expected to enhance market share and accelerate growth in overseas markets [2][4][5]. - In 2025, the implementation of a national subsidy policy for home medical devices in China, providing a 30% subsidy for home respiratory devices, is expected to drive domestic market growth. The domestic market share for 瑞迈特 is currently 30%, and transitioning from distributor to direct sales in e-commerce channels is anticipated to boost revenue and margins [4][15]. Industry Dynamics and Competitive Landscape - The core technology in the respiratory device industry includes key components like fans, which affect noise and performance. 瑞迈特 currently has no patent disputes with Resmed, and the competitive landscape has shifted following Philips' exit from the US market, leaving Resmed as the dominant player and 瑞迈特 in second place [2][6]. - The demand for home respiratory devices is primarily driven by patients with Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA). In China, there are approximately 100 million COPD patients with a low diagnosis rate, and the potential market for home respiratory devices is substantial [7]. Product Development and Market Position - 瑞迈特's new noise-free respiratory device has been designed to mitigate risks associated with traditional noise-absorbing materials, which led to Philips' product recalls. This new device has comparable respiratory response capabilities to Resmed's latest S11 model [12][13]. - The company’s products are now on par with leading international brands, although there are still minor differences in noise control. The focus on comfort in mask design is crucial for user preference [11][12]. Future Growth Expectations - The company is projected to achieve growth rates of 25% to 30% over the next three years, with a focus on overseas sales and new product launches. Attention is needed on the progress of these initiatives and the regulatory environment in the US [16]. - The absence of tariffs on respiratory devices entering the US market, as per the relevant agreements, alleviates concerns regarding trade barriers for 瑞迈特 and its competitors [17]. Additional Considerations - The integration of cloud platforms to connect with hospital markets and the expansion into regions like Europe, the Middle East, and South America through distributors are seen as promising avenues for growth [4][14]. - The overall industry growth in China is expected to outpace global growth due to favorable policies and market dynamics [15].

Group 1 - The core business of the company is the manufacturing of medical devices and consumables in the respiratory health field, including various types of sleep breathing machines and monitoring devices [2] - As of March 31, 2025, the company had 9,118 shareholders, an increase of 1,481 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company's latest quarterly report for Q1 2025 shows a revenue of 265 million yuan, a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, a year-on-year increase of 44.11%, with a gross profit margin of 49.57% [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 48.82, while the industry average PE ratio is 57.48, and the industry median is 40.95, placing the company at the 85th position in the industry ranking [1][3] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents [2]

Group 1 - The company, Ruimaite (301367), announced that its semi-annual report for 2025 is expected to be disclosed on August 28, 2025 [1] - The report will include information on the number of shareholders as of June 30, 2025 [1]